ReviewAllergy2022
Managing the allergy and asthma epidemic in 2020s-Lessons from the Finnish experience.
Review in Allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Global Asthma Disparities: Deciphering the Multifaceted Environmental Exposome Between Eastern and Western Populations.Clinical reviews in allergy & immunology · 2026Review
- Early Risk Assessment and Recognition of Allergies in Children: Rationale, Methodology, and Proposed Algorithms.Allergy · 2026Review
- Allergy prevention-a new public health perspective.European journal of public health · 2026Article
- Nature prescription for patients with chronic respiratory diseases.The World Allergy Organization journal · 2026Review
- Asthma Awareness Questionnaire: Development, Psychometric Validation, and Extent.Pulmonary therapy · 2026Article
- Dietary fructo-oligosaccharides dose-dependently modulate the microbiome and suppress type 2 lung inflammation in a murine model of house dust mite-induced allergic asthma.Frontiers in nutrition · 2026Article
- Observational
- Increased risk of IgE-mediated allergies in patients with celiac disease: a case-control study.Frontiers in nutrition · 2025Article
- Impact of Asthma Severity and Exacerbation Frequency on Burden of Disease Related Costs in Finland.Journal of asthma and allergy · 2025Article
- Lifestyle Changes and Industrialization in the Development of Allergic Diseases.Current allergy and asthma reports · 2024Review
- Knowledge mapping of links between dendritic cells and allergic diseases: A bibliometric analysis (2004-2023).Heliyon · 2024Article
- [Global environmental changes and the epithelial barrier hypothesis].Dermatologie (Heidelberg, Germany) · 2024Review
- Effect of altered human exposome on the skin and mucosal epithelial barrier integrity.Tissue barriers · 2023Article
- Role of Small Molecule Ligands in IgE-Mediated Allergy.Current allergy and asthma reports · 2023Review
- A short history from Karelia study to biodiversity and public health interventions.Frontiers in allergy · 2023Review
- Managing the allergy and asthma epidemic in 2020s-Lessons from the Finnish experience.Allergy · 2022Review
- Knowledge mapping of the links between the microbiota and allergic diseases: A bibliometric analysis (2002-2021).Frontiers in immunology · 2022Article
- Article
- Kinesin family member 3A induces related diseases via wingless-related integration site/β-catenin signaling pathway.Science progressReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Finland, a systematic public health programme was implemented from 2008 to 2018 to mitigate the burden of allergic disorders by revisiting the prevention strategy. Allergy health and contacts with natural environment were emphasized to promote immunological and psychological resilience instead of poorly justified avoidance. Allergy management practices were improved and low-valued recommendations for care, for example for food allergy, were revised. Patients and families were empowered to use guided self-management to proactively stop symptom exacerbations. A professional non-governmental organization implemented the nationwide education for healthcare and patient NGOs for patients, families and lay public. In healthcare, the work supporting allergic patients and families was organized towards common goals and integrated into everyday work without extra costs. Reaching the predefined goals was followed by employing the national healthcare registers and questionnaire surveys. Governmental bodies contributed with kick-off funding, which was supplemented by private funding. International collaboration, for example with the European patient organization (EFA), increased awareness of the Finnish action and predisposed it for peer review. The 10-year results are favourable, patients are less disabled, practices and attitudes in healthcare have changed, and major cost savings have been obtained. Views of the lay public and patients are slow to move, however. Local multidisciplinary allergy teams were set up to continue the activities also after the Programme. Changes in environment and lifestyle in the last 50 years are the main reasons for the allergy rise. The Finnish experience may help to manage allergic diseases, improve nature relatedness in the fast-urbanizing world, combat nature loss and reduce the disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.